Cancer Vaccines : Challenges and Opportunities in Translation book cover
1st Edition

Cancer Vaccines
Challenges and Opportunities in Translation

ISBN 9780367387556
Published October 18, 2019 by CRC Press
238 Pages

FREE Standard Shipping
USD $29.95

Prices & shipping based on shipping country


Book Description

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: Challenges and Opportunities in Translation is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.

Cancer Vaccines: Challenges and Opportunities in Translation:

  • Critically analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potential

  • Discusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapy

  • Presents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancer

  • Reviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them

Table of Contents

SECTION I - Basic Aspects: Tumor Antigens and Preclinical Modelling. 1. Factoring in antigen processing in designing anti-tumor T-cell vaccines. 2. Outlining the gap between preclinical models and clinical situation. SECTION II - Cell Based, Anti-infectious and Personalized Vaccines. 3. THERAPEUTIC AND PROPHYLACTIC CANCER VACCINES - EMERGING PERSPECTIVES FROM ALLOGENEIC AND INFECTIOUS DISEASE VACCINES. 4. Personalized Cancer Vaccines. 5. Dendritic cell vaccines for gliomas. SECTION III. INTRACEREBRAL HEMORRHAGE (ICH). 6. Peptide based active immunotherapy in cancer. 7. Multimodality Immunization Approaches to Improve on DNA Vaccines for Cancer. 8. Bidirectional Bedside Lab Bench Processes and Flexible Trial Design as a Means to Expedite the Development of Novel Immunotherapeutics. 9. Diagnostic approaches for selecting patient-customized therapies, obviating tumor variability to maximize therapeutic effect.

View More



ADRIAN BOT is Senior Director of Scientific Management and Acting Head of Translational Medicine at MannKind Corporation, in Valencia, California. He obtained his M.D. at the University of Medicine and Pharmacy in Timisoara, Romania and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York. He previously held appointments at the Scripps Research Institute and Alliance Pharmaceutical Corporation in San Diego. Dr. Bot authored more than one hundred publications and patents in oncology, vaccines, drug delivery technologies and immunotherapy. He is the Editor-in-Chief of the International Reviews of Immunology and has been on advisory boards of several organizations.

MIHAIL OBROCEA is Vice President, Clinical Development, MannKind Corporation, Paramus, New Jersey. Dr. Obrocea received his M.D. from the Faculty of Medicine and Pharmacy, Bucharest, Romania. He is a medical oncologist with over 10 years of academic and industry experience in oncology clinical trials, including biologic agents, small molecules and cytotoxic agents. Dr. Obrocea has published in oncology peer-reviewed literature, and has various patents in the field of biotechnology.